Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has demonstrated renoprotective effects in randomized controlled trials. However, real-world evidence, particularly in heterogeneous and non-diabetic chronic kidney disease (CKD) populations, remains limited. Methods: This was a single-center, retrospective, real-world cohort study of adults with non-diabetic CKD who initiated finerenone.
Abstract Light-chain proximal tubulopathy (LCPT) is a rare renal manifestation of monoclonal gammopathy that is exceptionally uncommon in Waldenström macroglobulinemia (WM). We report a case of crystalline κ-LCPT in WM and conduct a literature review of WM-associated LCPT and crystal-storing histiocytosis (CSH). A 65-year-old man with a 4-year history of intermittent hematuria and proteinuria developed progressive renal dysfunction.
Abstract IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of end-stage renal disease. Finerenone reduces proteinuria in diabetic kidney disease, but evidence in IgAN remains limited. This single-center retrospective study included adults with biopsy-proven IgAN who initiated finerenone therapy between January 2023 and December 2025 and were followed for at least 90 days.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
